Ivonescimab

Analysts predict a modest increase in M&A activity in 2025, with Viking Therapeutics leading as a prime acquisition target due to its obesity and MASH drug pipelines. Viking's VK2735 and VK2809 show promising results, positioning it favorably for Big Pharma interest. Other biotechs like Madrigal, Summit, and Sarepta are also seen as top M&A candidates.

Akeso, Inc. will participate in the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, in San Francisco. CEO Dr. Michelle Xia will present updates on leading programs like ivonescimab, cadonilimab, and ligufalimab. Akeso focuses on innovative biological medicines, with over 50 assets in development and 22 in clinical trials.

Motley Fool contributors predict Amgen, Eli Lilly, and Summit Therapeutics as top healthcare stocks for 2025. Amgen's potential rebound from a sell-off, Eli Lilly's promising pipeline and financials, and Summit's late-stage study results for NSCLC treatment highlight their growth prospects.

Clinical trial results in 2025 could significantly impact pharmaceutical stocks, focusing on obesity, oncology, Alzheimer’s, and vaccines. Key players include Eli Lilly, Novo Nordisk, BioNTech, Pfizer, and AbbVie, with potential breakthroughs in treatments and vaccines.

Summit Therapeutics Inc (SMMT) will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, showcasing ivonescimab, a bispecific antibody in Phase III trials for NSCLC, with Fast Track FDA designation. Despite potential, risks remain in clinical trials and regulatory approvals.

In 2024, the S&P 500 rose over 24%, Nasdaq by nearly 32%, and Dow by almost 13%, with large-cap growth and tech stocks performing well. Nvidia led the Magnificent Seven with a 184% increase. Top large-cap performers included AppLovin (740%), Summit Therapeutics (587%), Rocket Lab (397%), Palantir (363%), and MicroStrategy (351%).

Motley Fool contributors highlight Novo Nordisk, Summit Therapeutics, and Viking Therapeutics as potential 2025 stock winners, citing growth prospects in healthcare and biotech sectors.

Ivonescimab combined with chemotherapy showed a median progression-free survival of 9.36 months in patients with advanced triple-negative breast cancer, demonstrating promising antitumor activity and a manageable safety profile.

Edmund Ingham suggests diversifying biotech investments across sizes, including dividend-paying pharma, commercial-stage, and speculative clinical-stage companies. Key 2025 developments include Eli Lilly potentially reaching a trillion-dollar market cap and the growth of GLP-1 weight loss drugs. Lower interest rates may boost biotech investment, and the sector's resilience is highlighted by recent IPOs. Ingham is optimistic about 2025, focusing on GLP-1 drugs' commercial performance and the potential for significant industry growth.